Latest Avidity Partners Management LP Stock Portfolio
Avidity Partners Management LP Performance:
2024 Q3: 5.1%YTD: 12.2%2023: 6.74%
Performance for 2024 Q3 is 5.1%, and YTD is 12.2%, and 2023 is 6.74%.
About Avidity Partners Management LP and 13F Hedge Fund Stock Holdings
Avidity Partners Management LP is a hedge fund based in DALLAS, TX. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.2 Billions. In it's latest 13F Holdings report, Avidity Partners Management LP reported an equity portfolio of $2 Billions as of 30 Sep, 2024.
The top stock holdings of Avidity Partners Management LP are BSX, , ISRG. The fund has invested 4.1% of it's portfolio in BOSTON SCIENTIFIC CORP and 4.1% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off THE CIGNA GROUP (CI), ALNYLAM PHARMACEUTICALS INC (ALNY) and REGENERON PHARMACEUTICALS (REGN) stocks. They significantly reduced their stock positions in IMMUNOVANT INC (IMVT), CULLINAN THERAPEUTICS INC (CGEM) and APOGEE THERAPEUTICS INC. Avidity Partners Management LP opened new stock positions in UNITEDHEALTH GROUP INC (UNH), HUMANA INC (HUM) and CENTESSA PHARMACEUTICALS PLC (CNTA). The fund showed a lot of confidence in some stocks as they added substantially to EDITAS MEDICINE INC (EDIT), EXACT SCIENCES CORP (EXAS) and NEWAMSTERDAM PHARMA COMPANY (NAMS).
The top stock holdings of Avidity Partners Management LP are BSX, , ISRG. The fund has invested 4.1% of it's portfolio in BOSTON SCIENTIFIC CORP and 4.1% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off THE CIGNA GROUP (CI), ALNYLAM PHARMACEUTICALS INC (ALNY) and REGENERON PHARMACEUTICALS (REGN) stocks. They significantly reduced their stock positions in IMMUNOVANT INC (IMVT), CULLINAN THERAPEUTICS INC (CGEM) and APOGEE THERAPEUTICS INC. Avidity Partners Management LP opened new stock positions in UNITEDHEALTH GROUP INC (UNH), HUMANA INC (HUM) and CENTESSA PHARMACEUTICALS PLC (CNTA). The fund showed a lot of confidence in some stocks as they added substantially to EDITAS MEDICINE INC (EDIT), EXACT SCIENCES CORP (EXAS) and NEWAMSTERDAM PHARMA COMPANY (NAMS).
Avidity Partners Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Avidity Partners Management LP made a return of 5.1% in the last quarter. In trailing 12 months, it's portfolio return was 26.57%.
New Buys
| Ticker | $ Bought |
|---|---|
| unitedhealth group inc | 51,101,000 |
| humana inc | 41,081,200 |
| centessa pharmaceuticals plc | 34,090,700 |
| kymera therapeutics inc | 23,665,000 |
| biomarin pharmaceutical inc | 22,492,800 |
| oruka therapeutics inc | 19,385,600 |
| terns pharmaceuticals inc | 17,796,500 |
| ascendis pharma a/s | 17,767,900 |
New stocks bought by Avidity Partners Management LP
Additions
| Ticker | % Inc. |
|---|---|
| editas medicine inc | 79.53 |
| exact sciences corp | 73.71 |
| newamsterdam pharma company | 59.07 |
| glaukos corp | 53.97 |
| insmed inc | 37.67 |
| cg oncology inc | 27.76 |
| ideaya biosciences inc | 22.92 |
| perspective therapeutics inc | 13.38 |
Additions to existing portfolio by Avidity Partners Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| immunovant inc | -89.1 |
| cullinan therapeutics inc | -72.75 |
| apogee therapeutics inc | -68.38 |
| sanofi | -68.25 |
| establishment labs hldgs inc | -68.17 |
| abbvie inc | -64.00 |
| avantor inc | -59.98 |
| structure therapeutics inc | -59.92 |
Avidity Partners Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cybin inc | -9,453,560 |
| ac immune sa | -3,291,750 |
| jasper therapeutics inc | -17,751,400 |
| legend biotech corp | -17,627,400 |
| immatics n.v | -4,567,820 |
| tyra biosciences inc | -5,964,270 |
| uipath inc | -4,590,160 |
| wave life sciences ltd | -1,746,500 |
Avidity Partners Management LP got rid off the above stocks
Sector Distribution
Avidity Partners Management LP has about 79.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 79.2 |
| Others | 19.2 |
| Basic Materials | 1.6 |
Market Cap. Distribution
Avidity Partners Management LP has about 37.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 31.9 |
| MID-CAP | 24.4 |
| UNALLOCATED | 20.3 |
| SMALL-CAP | 15.5 |
| MEGA-CAP | 5.8 |
| MICRO-CAP | 1.9 |
Stocks belong to which Index?
About 52.3% of the stocks held by Avidity Partners Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 47.7 |
| RUSSELL 2000 | 30 |
| S&P 500 | 22.3 |
Avidity Partners Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Avidity Partners Management LP
Avidity Partners Management LP has 81 stocks in it's portfolio. About 32% of the portfolio is in top 10 stocks. DXCM proved to be the most loss making stock for the portfolio. AVTR was the most profitable stock for Avidity Partners Management LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABBV | abbvie inc | 1.01 | 100,000 | 19,748,000 | reduced | -64.00 | ||
| ABIO | arca biopharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACHC | acadia healthcare company in | 3.19 | 985,000 | 62,458,800 | reduced | -12.05 | ||
| AGLE | spyre therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALNY | alnylam pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 1.88 | 1,497,000 | 36,871,100 | reduced | -49.9 | ||
| AVTR | avantor inc | 1.63 | 1,235,000 | 31,949,400 | reduced | -59.98 | ||
| AXSM | axsome therapeutics inc | 1.36 | 296,100 | 26,610,500 | reduced | -21.25 | ||
| BMRN | biomarin pharmaceutical inc | 1.15 | 320,000 | 22,492,800 | new | |||
| BMY | bristol-myers squibb co | 0.69 | 263,000 | 13,607,600 | new | |||
| BPMC | blueprint medicines corp | 1.49 | 315,000 | 29,137,500 | reduced | -17.75 | ||
| BSX | boston scientific corp | 4.11 | 962,000 | 80,615,600 | reduced | -17.78 | ||
| CGEM | cullinan therapeutics inc | 0.36 | 425,000 | 7,114,500 | reduced | -72.75 | ||
| CI | the cigna group | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CMAX | caremax inc | 0.00 | 21,200 | 36,040 | unchanged | 0.00 | ||
| CNTA | centessa pharmaceuticals plc | 1.74 | 2,132,000 | 34,090,700 | new | |||
| CNTX | context therapeutics inc | 0.74 | 7,417,160 | 14,537,600 | reduced | -0.03 | ||
| COGT | cogent biosciences inc | 0.55 | 1,001,000 | 10,810,800 | added | 0.03 | ||
| COLL | collegium pharmaceutical inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRBP | corbus pharmaceuticals hldgs | 0.00 | 0.00 | 0.00 | sold off | -100 | ||